Dr. Burstein on the Follow-Up of APT Trial for HER2+ Breast Cancer

Harold J. Burstein, MD, PhD
Published: Thursday, Jun 22, 2017



Harold J. Burstein, MD, PhD, senior physician, associate professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the 7-year follow-up of the APT trial investigating adjuvant paclitaxel and trastuzumab (Herceptin) for node-negative HER2-positive breast cancer.

In the initial results, there was a disease-free survival of 97%, explains Burstein. Those results were validated following the 7-year follow-up. Additionally, the instance of distant metastatic recurrence is low.

These follow-up results demonstrate that the patients on this trial have seen significant benefits, states Burstein.
 


Harold J. Burstein, MD, PhD, senior physician, associate professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the 7-year follow-up of the APT trial investigating adjuvant paclitaxel and trastuzumab (Herceptin) for node-negative HER2-positive breast cancer.

In the initial results, there was a disease-free survival of 97%, explains Burstein. Those results were validated following the 7-year follow-up. Additionally, the instance of distant metastatic recurrence is low.

These follow-up results demonstrate that the patients on this trial have seen significant benefits, states Burstein.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x